Do analysts rate XGN or RYOJ?

Exagen currently has a consensus price target of $9.63, suggesting a potential upside of 27.99%. Given Exagen's stronger consensus rating and higher possible upside, research analysts clearly believe Exagen is more favorable than RYOJ. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, XGN or RYOJ?

RYOJ has lower revenue, but higher earnings than Exagen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 2.74 -$19.95M -$0.81 N/A RYOJ $9.34M 7.59 $120K N/A N/A

Is XGN or RYOJ more profitable?

RYOJ has a net margin of 0.00% compared to Exagen's net margin of -26.61%. RYOJ's return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% RYOJ N/A N/A N/A

Does the media favor XGN or RYOJ?

In the previous week, Exagen and Exagen both had 3 articles in the media. Exagen's average media sentiment score of 1.08 beat RYOJ's score of 0.96 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RYOJ 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RYOJ or LFMD?

LifeMD has a consensus price target of $7.57, suggesting a potential upside of 132.25%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than RYOJ. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has better valuation & earnings, RYOJ or LFMD?

LifeMD has higher revenue and earnings than RYOJ. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 7.59 $120K N/A N/A LifeMD $194.05M 0.81 $14.35M -$0.05 N/A

Is RYOJ or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to RYOJ's net margin of 0.00%. RYOJ's return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets RYOJ N/A N/A N/A LifeMD 0.10% -168.23% -31.27%

Does the media prefer RYOJ or LFMD?

In the previous week, RYOJ had 1 more articles in the media than LifeMD. MarketBeat recorded 3 mentions for RYOJ and 2 mentions for LifeMD. RYOJ's average media sentiment score of 0.96 beat LifeMD's score of 0.94 indicating that RYOJ is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RYOJ 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer JYNT or RYOJ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, JYNT or RYOJ?

Joint has higher revenue and earnings than RYOJ. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.17 $2.91M $0.27 31.15 RYOJ $9.34M 7.59 $120K N/A N/A

Is JYNT or RYOJ more profitable?

Joint has a net margin of 6.49% compared to RYOJ's net margin of 0.00%. Joint's return on equity of 12.02% beat RYOJ's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% RYOJ N/A N/A N/A

Does the media refer more to JYNT or RYOJ?

In the previous week, RYOJ had 1 more articles in the media than Joint. MarketBeat recorded 3 mentions for RYOJ and 2 mentions for Joint. RYOJ's average media sentiment score of 0.96 beat Joint's score of 0.93 indicating that RYOJ is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RYOJ 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RYOJ or PARK?

Park Dental Partners has a consensus price target of $28.50, suggesting a potential upside of 30.85%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts clearly believe Park Dental Partners is more favorable than RYOJ. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Park Dental Partners 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings and valuation, RYOJ or PARK?

RYOJ has higher earnings, but lower revenue than Park Dental Partners. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 7.59 $120K N/A N/A Park Dental Partners $244.49M 0.42 -$360K $1.05 20.74

Is RYOJ or PARK more profitable?

Company Net Margins Return on Equity Return on Assets RYOJ N/A N/A N/A Park Dental Partners N/A N/A N/A

Does the media favor RYOJ or PARK?

In the previous week, RYOJ and RYOJ both had 3 articles in the media. Park Dental Partners' average media sentiment score of 1.74 beat RYOJ's score of 0.96 indicating that Park Dental Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RYOJ 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Park Dental Partners 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend RYOJ or ACH?

Accendra Health has a consensus price target of $1.50, indicating a potential upside of 23.46%. Given Accendra Health's stronger consensus rating and higher probable upside, analysts plainly believe Accendra Health is more favorable than RYOJ. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Accendra Health 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has preferable earnings and valuation, RYOJ or ACH?

RYOJ has higher earnings, but lower revenue than Accendra Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 7.59 $120K N/A N/A Accendra Health $2.73B 0.03 -$1.10B -$3.91 N/A

Does the media prefer RYOJ or ACH?

In the previous week, RYOJ and RYOJ both had 3 articles in the media. Accendra Health's average media sentiment score of 1.16 beat RYOJ's score of 0.96 indicating that Accendra Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RYOJ 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Accendra Health 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

RYOJ (RYOJ) Competitors

$6.14 +0.28 (+4.78%)

Closing price 04:00 PM Eastern

Extended Trading

$6.04 -0.11 (-1.71%)

As of 07:54 PM Eastern

Compare

RYOJ vs. XGN, LFMD, JYNT, PARK, and ACH

Should you buy RYOJ stock or one of its competitors? RYOJ's main competitors and comparable companies include Exagen (XGN), LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), and Accendra Health (ACH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does RYOJ compare to Exagen?

Exagen (NASDAQ:XGN) and RYOJ (NASDAQ:RYOJ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

RYOJ has lower revenue, but higher earnings than Exagen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.74	-$19.95M	-$0.81	N/A
RYOJ	$9.34M	7.59	$120K	N/A	N/A

RYOJ has a net margin of 0.00% compared to Exagen's net margin of -26.61%. RYOJ's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
RYOJ	N/A	N/A	N/A

75.3% of Exagen shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Exagen currently has a consensus price target of $9.63, suggesting a potential upside of 27.99%. Given Exagen's stronger consensus rating and higher possible upside, research analysts clearly believe Exagen is more favorable than RYOJ.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Exagen and Exagen both had 3 articles in the media. Exagen's average media sentiment score of 1.08 beat RYOJ's score of 0.96 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RYOJ	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exagen beats RYOJ on 8 of the 13 factors compared between the two stocks.

How does RYOJ compare to LifeMD?

RYOJ (NASDAQ:RYOJ) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

LifeMD has a consensus price target of $7.57, suggesting a potential upside of 132.25%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than RYOJ.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, RYOJ had 1 more articles in the media than LifeMD. MarketBeat recorded 3 mentions for RYOJ and 2 mentions for LifeMD. RYOJ's average media sentiment score of 0.96 beat LifeMD's score of 0.94 indicating that RYOJ is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RYOJ	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.5% of LifeMD shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LifeMD has a net margin of 0.10% compared to RYOJ's net margin of 0.00%. RYOJ's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
LifeMD	0.10%	-168.23%	-31.27%

LifeMD has higher revenue and earnings than RYOJ.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	7.59	$120K	N/A	N/A
LifeMD	$194.05M	0.81	$14.35M	-$0.05	N/A

Summary

LifeMD beats RYOJ on 8 of the 13 factors compared between the two stocks.

How does RYOJ compare to Joint?

Joint (NASDAQ:JYNT) and RYOJ (NASDAQ:RYOJ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Joint has a net margin of 6.49% compared to RYOJ's net margin of 0.00%. Joint's return on equity of 12.02% beat RYOJ's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
RYOJ	N/A	N/A	N/A

In the previous week, RYOJ had 1 more articles in the media than Joint. MarketBeat recorded 3 mentions for RYOJ and 2 mentions for Joint. RYOJ's average media sentiment score of 0.96 beat Joint's score of 0.93 indicating that RYOJ is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Joint	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RYOJ	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.9% of Joint shares are held by institutional investors. 30.2% of Joint shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Joint has higher revenue and earnings than RYOJ.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.17	$2.91M	$0.27	31.15
RYOJ	$9.34M	7.59	$120K	N/A	N/A

Summary

Joint beats RYOJ on 8 of the 11 factors compared between the two stocks.

How does RYOJ compare to Park Dental Partners?

RYOJ (NASDAQ:RYOJ) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

In the previous week, RYOJ and RYOJ both had 3 articles in the media. Park Dental Partners' average media sentiment score of 1.74 beat RYOJ's score of 0.96 indicating that Park Dental Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RYOJ	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Park Dental Partners	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
Park Dental Partners	N/A	N/A	N/A

RYOJ has higher earnings, but lower revenue than Park Dental Partners.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	7.59	$120K	N/A	N/A
Park Dental Partners	$244.49M	0.42	-$360K	$1.05	20.74

Park Dental Partners has a consensus price target of $28.50, suggesting a potential upside of 30.85%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts clearly believe Park Dental Partners is more favorable than RYOJ.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Park Dental Partners beats RYOJ on 6 of the 8 factors compared between the two stocks.

How does RYOJ compare to Accendra Health?

RYOJ (NASDAQ:RYOJ) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

RYOJ has a net margin of 0.00% compared to Accendra Health's net margin of -11.41%. RYOJ's return on equity of 0.00% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
Accendra Health	-11.41%	-4.02%	0.70%

In the previous week, RYOJ and RYOJ both had 3 articles in the media. Accendra Health's average media sentiment score of 1.16 beat RYOJ's score of 0.96 indicating that Accendra Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RYOJ	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accendra Health	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Accendra Health has a consensus price target of $1.50, indicating a potential upside of 23.46%. Given Accendra Health's stronger consensus rating and higher probable upside, analysts plainly believe Accendra Health is more favorable than RYOJ.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

RYOJ has higher earnings, but lower revenue than Accendra Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	7.59	$120K	N/A	N/A
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A

Summary

Accendra Health beats RYOJ on 5 of the 9 factors compared between the two stocks.

Get RYOJ News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYOJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYOJ vs. The Competition

Export

Metric	RYOJ	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$67.68M	$10.05B	$7.31B	$12.78B
Dividend Yield	N/A	2.55%	2.53%	11.03%
P/E Ratio	N/A	29.48	210.50	22.08
Price / Sales	7.59	5.04	630.29	95.53
Price / Cash	113.66	126.73	79.17	53.57
Price / Book	11.37	4.10	13.01	6.26
Net Income	$120K	$312.92M	$3.46B	$348.07M
7 Day Performance	30.36%	0.59%	1.95%	1.40%
1 Month Performance	61.58%	1.13%	8.17%	4.59%
1 Year Performance	N/A	16.10%	26.28%	17.05%

RYOJ Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYOJ RYOJ	1.1499 of 5 stars	$6.14 +4.8%	N/A	N/A	$67.68M	$9.34M	N/A	N/A	Short Interest Decrease
XGN Exagen	3.6466 of 5 stars	$7.92 +1.8%	$9.63 +21.5%	-22.5%	$191.86M	$71.12M	N/A	220
LFMD LifeMD	3.5255 of 5 stars	$3.31 +0.9%	$7.57 +128.7%	-50.2%	$159.55M	$191.59M	N/A	230
JYNT Joint	2.3027 of 5 stars	$8.44 +2.3%	N/A	-21.5%	$119.34M	$54.90M	31.26	320
PARK Park Dental Partners	4.3144 of 5 stars	$20.61 -4.9%	$28.50 +38.3%	N/A	$98.10M	$244.49M	19.63	1,212

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYOJ) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RYOJ (RYOJ) Competitors